01573nas a2200337   4500000000100000008004100001260001300042653002600055653003100081653001500112653002500127653003100152653003200183653001300215653002500228653003100253653001500284653003200299100001000331700001300341700001500354700001400369700001500383700001500398700001300413245017400426300001000600490000700610520060400617022001401221       2011                            d  c2011 Feb10aAnti-Bacterial Agents10aBacteriological Techniques10aDNA gyrase10aDNA Topoisomerase IV10aDrug Resistance, Bacterial10aMicrobial Sensitivity Tests10aMutation10aMycobacterium leprae10aMycobacterium tuberculosis10aQuinolones10aTopoisomerase II Inhibitors1 aKim H1 aSuzuki H1 aMatsuoka M1 aMatsuba T1 aYokoyama K1 aNakajima C1 aSuzuki Y00a[Molecular mechanism of the acquisition of new-quinolone resistance in Mycobacterium leprae and M. tuberculosis and rapid differentiation methods for resistant bacilli].  a17-270 v803 a<p>Drugs included in new-quinolone are used for the treatment of leprosy with single lesion. These drugs are also known to be effective drugs for the treatment of multi-drug resistant M. tuberculosis. Recent emergence of new-quinolone resistant M. leprae and M. tuberculosis enforced the urgent elucidation of the mode of emergence of new-quinolone resistant strains. In this review, new-quinolone drugs, their mode of action and mechanism of acquisition of resistance by M. leprae and M. tuberculosis were explained. And rapid differentiation methods for resistant bacilli were also introduced.</p>  a1342-3681